TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07180355: A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

Sponsor: Solid Biosciences Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$496,672

Rescue Site Savings

+$338,640

Unlock Full NCT07180355 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07180355 Rescue Dossier →